Skip to main content
. 2015 Jul 20;6(28):26029–26040. doi: 10.18632/oncotarget.4347

Figure 3. Bicalutamide-driven ARW741L activity and LNCaP-ARW741L cell growth is attenuated by enzalutamide.

Figure 3

A. LNCaP-ARW741L cells depleted of endogenous AR were treated with 10 nM bicalutamide +/− 10 μM enzalutamide for 24 hours prior to quantitative analysis of AR target gene expression. B. LNCaP-ARW741L cells transfected with siScr or siART877A were treated for 4 hours with either 1 nM DHT or bicalutamide +/− 10 μM enzalutamide prior to ChIP and quantitative PCR analysis using primers specific to AR-target genes. C. LNCaP cells or the LNCaP-ARW741L derivative depleted of endogenous or ectopic AR were grown in the presence of 1 nM DHT, 10 nM bicalutamide or 10 μM enzalutamide for 96 hours prior to SRB staining. Percentage growth is relative to vehicle control for each siRNA. Data is the mean of triplicate experiments ± standard error. D. As for (C) except LNCaP-ARW741L cells depleted of endogenous AR were treated with 10 nM bicalutamide +/− increasing doses of enzalutamide to a maximum of 30 μM prior to SRB staining.